SCHEMBL11949653

SCHEMBL11949653

Cc1cnc(NC(=O)C2CCC(Cn3cnc4ccccc4c3=O)CC2)s1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ RAB9A P51151 2/20 0.48
▸ ALDH1A1 P00352 4/20 0.47
▸ RXFP1 Q9HBX9 3/20 0.47
▸ HTT P42858 2/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ HPGD P15428 2/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ LMNA P02545 1/20 0.43
▸ CHKA P35790 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11949637 0.84 KDM4E (0.66) MAPTSMN1; SMN2RAB9AALDH1A1RXFP1
SCHEMBL11949649 0.83 GCK (0.56) MAPTSMN1; SMN2ALDH1A1RXFP1HTT
SCHEMBL11949642 0.82 MAPT (0.53) MAPTSMN1; SMN2RAB9ARXFP1HTT
SCHEMBL11949645 0.81 MAPT (0.52) MAPTSMN1; SMN2RAB9AALDH1A1RXFP1
SCHEMBL11949657 0.81 MAPT (0.50) MAPTSMN1; SMN2RAB9AALDH1A1RXFP1
SCHEMBL11949643 0.81 MAPT (0.51) MAPTSMN1; SMN2HTTMEN1KMT2A
SCHEMBL11949639 0.80 RAB9A (0.50) MAPTSMN1; SMN2RAB9AALDH1A1HTT
SCHEMBL11949736 0.79 MAPT (0.53) MAPTSMN1; SMN2RAB9AHTTNPC1
SCHEMBL11949735 0.78 SMN1; SMN2 (0.54) MAPTSMN1; SMN2RAB9AALDH1A1HTT
SCHEMBL11949648 0.78 MAPT (0.58) MAPTSMN1; SMN2RAB9AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8865704-B2 Wnt pathway antagonists SIENA BIOTECH S.P.A. (IT) 2014-10-21 — — US disclosed
US-8865704-B2 Wnt pathway antagonists SIENA BIOTECH S.P.A. (IT) 2014-10-21 — — US disclosed
US-20120196851-A1 WNT PATHWAY ANTAGONISTS SIENA BIOTECH S.P.A. (IT) 2012-08-02 — — US disclosed
US-20120196851-A1 WNT PATHWAY ANTAGONISTS SIENA BIOTECH S.P.A. (IT) 2012-08-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196851-A1 WNT PATHWAY ANTAGONISTS WNT1, WNT3A, CTNNB1 MAPT 4418/4885SMN1; SMN2 4677/4885RAB9A 1935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback